AC Immune doses first patients in final ABATE trial cohort

April 30, 2026 7:01 AM

AC Immune SA (NASDAQ: ACIU) has dosed the first patients in Cohort AD4, the final cohort of its ongoing Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found